BTIG Maintains Buy on Spyre Therapeutics, Raises Price Target to $132
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $112 to $132.
BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $112 to $132.